We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.
- Authors
Bolan, Patrick J.; Kim, Eunhee; Herman, Benjamin A.; Newstead, Gillian M.; Rosen, Mark A.; Schnall, Mitchell D.; Pisano, Etta D.; Weatherall, Paul T.; Morris, Elizabeth A.; Lehman, Constance D.; Garwood, Michael; Nelson, Michael T.; Yee, Douglas; Polin, Sandra M.; Esserman, Laura J.; Gatsonis, Constantine A.; Metzger, Gregory J.; Newitt, David C.; Partridge, Savannah C.; Hylton, Nola M.
- Abstract
<bold>Purpose: </bold>To estimate the accuracy of predicting response to neoadjuvant chemotherapy (NACT) in patients with locally advanced breast cancer using MR spectroscopy (MRS) measurements made very early in treatment.<bold>Materials and Methods: </bold>This prospective Health Insurance Portability and Accountability Act (HIPAA)-compliant protocol was approved by the American College of Radiology and local-site institutional review boards. One hundred nineteen women with invasive breast cancer of ≥3 cm undergoing NACT were enrolled between September 2007 and April 2010. MRS measurements of the concentration of choline-containing compounds ([tCho]) were performed before the first chemotherapy regimen (time point 1, TP1) and 20-96 h after the first cycle of treatment (TP2). The change in [tCho] was assessed for its ability to predict pathologic complete response (pCR) and radiologic response using the area under the receiver operating characteristic curve (AUC) and logistic regression models.<bold>Results: </bold>Of the 119 subjects enrolled, only 29 cases (24%) with eight pCRs provided usable data for the primary analysis. Technical challenges in acquiring quantitative MRS data in a multi-site trial setting limited the capture of usable data. In this limited data set, the decrease in tCho from TP1 to TP2 had poor ability to predict either pCR (AUC = 0.53, 95% confidence interval [CI]: 0.27-0.79) or radiologic response (AUC = 0.51, 95% CI: 0.27-0.75).<bold>Conclusion: </bold>The technical difficulty of acquiring quantitative MRS data in a multi-site clinical trial setting led to a low yield of analyzable data, which was insufficient to accurately measure the ability of early MRS measurements to predict response to NACT.<bold>Level Of Evidence: </bold>1 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;46:290-302.
- Subjects
BREAST tumor diagnosis; BREAST tumor treatment; DISEASE relapse prevention; ALGORITHMS; BREAST tumors; CHOLINE; CLINICAL trials; COMPARATIVE studies; DIAGNOSTIC imaging; RESEARCH methodology; MEDICAL cooperation; MOLECULAR diagnosis; NUCLEAR magnetic resonance spectroscopy; RESEARCH; RESEARCH evaluation; RESEARCH funding; EVALUATION research; EARLY detection of cancer
- Publication
Journal of Magnetic Resonance Imaging, 2017, Vol 46, Issue 1, p290
- ISSN
1053-1807
- Publication type
journal article
- DOI
10.1002/jmri.25560